Physician profile
Gerardo Arias
NPI 1447265178
$2,752.88
in general payments reported to CMS, 2019-2025
44 companies · $497 in 2025
The $497 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $96.10 · 2021: $11.92 · 2022: $393 · 2023: $1,065 · 2024: $690 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,209 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,208.96 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $356.71 | 2023 | Myrisk |
| Novartis Pharmaceuticals Corporation | $271.72 | 2022-2025 | |
| Lilly USA, LLC | $177.22 | 2020-2024 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $157.85 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $122.54 | 2022-2025 | Enhertu |
| Exelixis INC. | $119.54 | 2022-2025 | Cabometyx |
| Daiichi Sankyo INC. | $97.57 | 2023-2025 | Enhertu, Datroway |
| Beigene USA, INC. | $96.31 | 2022-2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $94.53 | 2022-2025 | Opdivo, Camzyos, Opdualag |
| Astellas Pharma US INC | $81.85 | 2023-2024 | Xtandi |
| Janssen Biotech, INC. | $73.91 | 2022-2025 | Tecvayli, Darzalex, Erleada |
| Genzyme Corporation | $63.34 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $63.30 | 2022-2024 | Keytruda |
| Glaxosmithkline, LLC. | $58.28 | 2022-2024 | Ojjaara |
| Adc Therapeutics America, INC. | $54.51 | 2023-2024 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Arias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.